Efficacy of montelukast in the treatment of chronic obstructive pulmonary disease in five horses.
Abstract: Five horses with moderate to severe chronic obstructive pulmonary disease (COPD) were treated with 0.11 (0.01) mg/kg bodyweight of montelukast, a cysteinyl leukotriene receptor antagonist, once a day for 26 days. The horses were evaluated clinically and endoscopically and subjected to arterial blood gas analysis and lung function tests before and after the period of treatment, and the plasma concentrations of montelukast were determined by high-performance liquid chromatography with fluorescence detection. The treatment did not result in statistically significant differences in the total scores of clinical and endoscopical signs, or in the difference in the arterioalveolar partial pressure of oxygen, maximal changes in pleural pressure, pulmonary resistance or dynamic compliance. The mean (sd) peak plasma concentration (C(max0) of montelukast was 12 (4) ng/ml and was reached 66 (13) minutes (t(max)) after its oral administration. The dose of montelukast per kg bodyweight was approximately the same as that for human beings, but the C(max) in the horses was 28 times lower and the t(max) was reached in one-fifth of the time, suggesting that its oral bioavailability may be lower.
Publication Date: 2003-07-17 PubMed ID: 12862169DOI: 10.1136/vr.152.26.804Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
- Animal Studies
- Asthma
- Chronic Obstructive Pulmonary Disease
- Clinical Examination
- Clinical Pathology
- Clinical Signs
- Clinical Study
- Disease Treatment
- Equine Health
- High-performance Liquid Chromatography (HPLC)
- Horses
- Lung Health
- Pharmacokinetics
- Pharmacology
- Plasma
- Pulmonary Health
- Respiratory Disease
- Veterinary Medicine
- Veterinary Research
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
This study examined the effectiveness of montelukast in treating chronic obstructive pulmonary disease (COPD) in five horses, however, found no significant improvements in clinical signs or physiological measures post-treatment.
Research Overview
- The researchers studied five horses with moderate to severe COPD.
- Montelukast, a cysteinyl leukotriene receptor antagonist, was administered to these horses daily for a period of 26 days. This drug is commonly utilized in the treatment of asthma in humans.
- The level of montelukast dosage was similar to the dose prescribed for humans, calculated per kilogram of body weight.
Evaluation Methods
- Throughout the study, the horses underwent regular clinical and endoscopic evaluations to monitor their symptoms and disease progression.
- Arterial blood gas analysis and lung function tests were conducted before and after the treatment period to assess the physiological changes in the horses.
- The plasma concentrations of montelukast in the horses were measured through high-performance liquid chromatography coupled with fluorescence detection.
Treatment Results
- The treatment didn’t result in significant improvements in either clinical or endoscopic signs of COPD in the horses.
- There were no significant differences in the arterioalveolar partial pressure of oxygen, maximal changes in pleural pressure, or dynamic compliance – all important measures in terms of lung function.
Pharmacological Analysis
- The mean peak plasma concentration (Cmax) of montelukast was found to be 12 (4) ng/ml, reached about 66 (13) minutes after oral administration.
- The concentration of montelukast in the blood of horses was 28 times lower than that observed in humans, and was reached five times faster, suggesting that the bioavailability of the drug may be lower in horses than in humans.
Conclusion
- This research suggests that at the doses used in the study, montelukast may not be as effective in treating COPD in horses as it is in humans. However, further research is warranted to evaluate the drug’s effectiveness at different doses, its bioavailability, and how it is metabolized in horses.
Cite This Article
APA
Kolm G, Zappe H, Schmid R, Riedelberger K, Van den Hoven R.
(2003).
Efficacy of montelukast in the treatment of chronic obstructive pulmonary disease in five horses.
Vet Rec, 152(26), 804-806.
https://doi.org/10.1136/vr.152.26.804 Publication
Researcher Affiliations
- University Clinic for Horses and Small Animals, Equine Department, University of Veterinary Science of Vienna, Veterinärplatz 1, A-1210 Vienna, Austria.
MeSH Terms
- Acetates / therapeutic use
- Animals
- Cyclopropanes
- Female
- Horse Diseases / drug therapy
- Horses
- Leukotriene Antagonists / therapeutic use
- Male
- Pulmonary Disease, Chronic Obstructive / classification
- Pulmonary Disease, Chronic Obstructive / drug therapy
- Pulmonary Disease, Chronic Obstructive / veterinary
- Quinolines / therapeutic use
- Respiration / drug effects
- Severity of Illness Index
- Sulfides
- Treatment Outcome
Citations
This article has been cited 2 times.- Wang H, Qu G. Observation of the Effect of Singulair Combined With Ketotifen in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease With Airway Hyperresponsiveness and Its Influence on Th17/Treg.. Front Surg 2022;9:848724.
- Rosenberg HF, Druey KM. Modeling asthma: Pitfalls, promises, and the road ahead.. J Leukoc Biol 2018 Jul;104(1):41-48.
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
